Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors

BACKGROUND: The phase I GATTO study (NCT03360734) explored the feasibility, tolerability and preliminary activity of combining gatipotuzumab, a novel humanized monoclonal antibody binding to the tumor-associated epitope of mucin 1 (TA-MUC1) and an anti-epidermal growth factor receptor (anti-EGFR) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ochsenreither, S., Fiedler, W.M., Conte, G.D., Macchini, M., Matos, I., Habel, B., Ahrens-Fath, I., Raspagliesi, F., Lorusso, D., Keilholz, U., Rolling, C., Kebenko, M., Klinghammer, K.F., Saavedra, O., Baumeister, H., Zurlo, A., Garralda, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058922/
https://www.ncbi.nlm.nih.gov/pubmed/35397434
http://dx.doi.org/10.1016/j.esmoop.2022.100447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058922/
https://www.ncbi.nlm.nih.gov/pubmed/35397434
http://dx.doi.org/10.1016/j.esmoop.2022.100447

Ejemplares similares